117 related articles for article (PubMed ID: 10520004)
21. High level of soluble interleukin-2 receptor in serum predicts treatment resistance and poor progression-free survival in multiple myeloma.
Wang L; Wang JH; Liu WJ; Wang WD; Wang H; Chen XQ; Geng QR; Lu Y; Xia ZJ
Ann Hematol; 2017 Dec; 96(12):2079-2088. PubMed ID: 28871325
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment.
Pecoits-Filho R; Bárány P; Lindholm B; Heimbürger O; Stenvinkel P
Nephrol Dial Transplant; 2002 Sep; 17(9):1684-8. PubMed ID: 12198224
[TBL] [Abstract][Full Text] [Related]
23. Serum oncostatin M in multiple myeloma: association with prognostic factors.
Koskela K; Pelliniemi TT; Remes K; Rajamäki A; Pulkki K
Br J Haematol; 1997 Jan; 96(1):158-60. PubMed ID: 9012701
[TBL] [Abstract][Full Text] [Related]
24. Soluble IL-6R in plasma cell dyscrasias.
Smith SR; Morgan L
Leuk Lymphoma; 1997 Aug; 26(5-6):489-95. PubMed ID: 9389356
[TBL] [Abstract][Full Text] [Related]
25. C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system.
Bataille R; Boccadoro M; Klein B; Durie B; Pileri A
Blood; 1992 Aug; 80(3):733-7. PubMed ID: 1638024
[TBL] [Abstract][Full Text] [Related]
26. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk.
Pulsatelli L; Boiardi L; Pignotti E; Dolzani P; Silvestri T; Macchioni P; Cantini F; Salvarani C; Facchini A; Meliconi R
Arthritis Rheum; 2008 Aug; 59(8):1147-54. PubMed ID: 18668607
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of determining serum soluble IL-6 receptor concentration in plasma cell dyscrasias].
Hou J; Zhao Y; Liu Y
Zhonghua Nei Ke Za Zhi; 1997; 36(2):94-6. PubMed ID: 9812567
[TBL] [Abstract][Full Text] [Related]
28. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
29. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
30. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
[TBL] [Abstract][Full Text] [Related]
31. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines.
Gaillard JP; Liautard J; Klein B; Brochier J
Eur J Immunol; 1997 Dec; 27(12):3332-40. PubMed ID: 9464821
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
33. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor.
Hargreaves PG; Wang F; Antcliff J; Murphy G; Lawry J; Russell RG; Croucher PI
Br J Haematol; 1998 Jun; 101(4):694-702. PubMed ID: 9674743
[TBL] [Abstract][Full Text] [Related]
34. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
35. Decreased soluble interleukin-6 receptor in patients with acute myocardial infarction.
Ueda K; Takahashi M; Ozawa K; Kinoshita M
Am Heart J; 1999 Nov; 138(5 Pt 1):908-15. PubMed ID: 10539822
[TBL] [Abstract][Full Text] [Related]
36. Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients.
Sasayama D; Wakabayashi C; Hori H; Teraishi T; Hattori K; Ota M; Ishikawa M; Arima K; Higuchi T; Amano N; Kunugi H
J Psychiatr Res; 2011 Nov; 45(11):1439-44. PubMed ID: 21700295
[TBL] [Abstract][Full Text] [Related]
37. Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma.
Greipp PR; Katzmann JA; O'Fallon WM; Kyle RA
Blood; 1988 Jul; 72(1):219-23. PubMed ID: 3291982
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis.
Fu Q; Chang Y; An H; Fu H; Zhu Y; Xu L; Zhang W; Xu J
Br J Cancer; 2015 Dec; 113(11):1581-9. PubMed ID: 26554658
[TBL] [Abstract][Full Text] [Related]
40. Serum interleukin-6 soluble receptor in relation to interleukin-6 in stroke patients.
Dziedzic T; Gryz EA; Turaj W; Slowik A; Szczudlik A
J Mol Neurosci; 2004; 24(2):293-8. PubMed ID: 15456942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
